Home › Companies › HALOZYME THERAPEUTICS INC. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and HALOZYME THERAPEUTICS INC.’s Form 8-K, filed May 2, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of May 1, 2025: 4 items on HALOZYME THERAPEUTICS INC.’s Form 8-K, filed May 2, 2025: 2 approved · 2 passed (calculated).
No notable dissent.
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore HALOZYME THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are HALOZYME THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 2, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Jeffrey W. Henderson | 98,993,463 | 3,298,117 | 95,045 | -- | 10,380,378 | 97% | Passed (calculated) | — |
| Elect Director: Helen I. Torley | 101,477,199 | 816,675 | 92,751 | -- | 10,380,378 | 99.2% | Passed (calculated) | — |
| 2. Advisory vote on the compensation of the Company's named executive officers | 98,252,464 | 3,966,034 | 168,127 | -- | 10,380,378 | 96% | Approved | — |
| 3. Proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 | 112,028,211 | 659,976 | 78,816 | -- | -- | 99.4% | Approved | — |
Source: HALOZYME THERAPEUTICS INC., Form 8-K, filed with the SEC on May 2, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
512 asset managers disclosed a vote on at least one HALOZYME THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
99.2% Majority: yes · of votes cast
Description as filed by funds: Election of Class III Directors: Helen I. Torley
HALOZYME THERAPEUTICS INC.’s own tally for this item (“Elect Director: Helen I. Torley”): 101,477,199 for, 816,675 against, per its Form 8-K filed May 2, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 136 asset managers below reported 56,859,508 for, 62,375 against, 46,609 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,665,245 | 0 | 0 | 0 | For |
| BlackRock | 9,674,728 | 0 | 0 | 0 | For |
| Fidelity | 3,221,194 | 0 | 0 | 0 | For |
| State Street | 3,087,240 | 0 | 0 | 0 | For |
| Invesco | 2,072,322 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,970,939 | 0 | 0 | 0 | For |
| Charles Schwab | 1,756,673 | 0 | 0 | 0 | For |
| Dimensional | 1,435,550 | 0 | 0 | 0 | For |
| TIAA | 1,297,097 | 0 | 0 | 0 | For |
| JPMorgan | 1,112,323 | 0 | 0 | 0 | For |
| T. Rowe Price | 894,936 | 0 | 0 | 0 | For |
| First Trust | 797,531 | 0 | 0 | 0 | For |
| Capital Group | 748,230 | 0 | 0 | 0 | For |
| Capitol Series Trust | 725,855 | 0 | 0 | 0 | For |
| American Century | 724,702 | 0 | 0 | 0 | For |
| AllianceBernstein | 705,155 | 0 | 0 | 0 | For |
| Putnam | 653,905 | 0 | 0 | 0 | For |
| Equitable | 637,751 | 0 | 0 | 0 | For |
| Artisan | 468,338 | 0 | 0 | 0 | For |
| PROFESSIONALLY MANAGED PORTFOLIOS | 456,742 | 0 | 0 | 0 | For |
| Victory Capital | 422,252 | 0 | 0 | 0 | For |
| Jackson National | 403,486 | 0 | 0 | 0 | For |
| GLENMEDE FUND INC | 386,531 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 378,160 | 0 | 0 | 0 | For |
| BOSTON TRUST WALDEN FUNDS | 359,876 | 0 | 0 | 0 | For |
Showing the 25 largest of 136 asset managers. All 136 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: Election of Class III Directors: Jeffrey W. Henderson
HALOZYME THERAPEUTICS INC.’s own tally for this item (“Elect Director: Jeffrey W. Henderson”): 98,993,463 for, 3,298,117 against, per its Form 8-K filed May 2, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 136 asset managers below reported 55,571,372 for, 1,236,011 against, 46,609 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,665,245 | 0 | 0 | 0 | For |
| BlackRock | 9,674,728 | 0 | 0 | 0 | For |
| Fidelity | 3,221,194 | 0 | 0 | 0 | For |
| State Street | 3,087,240 | 0 | 0 | 0 | For |
| Invesco | 2,072,322 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,970,939 | 0 | 0 | 0 | For |
| Charles Schwab | 1,756,673 | 0 | 0 | 0 | For |
| Dimensional | 1,435,550 | 0 | 0 | 0 | For |
| TIAA | 1,297,097 | 0 | 0 | 0 | For |
| JPMorgan | 1,112,323 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 894,936 | 0 | 0 | Against |
| First Trust | 797,531 | 0 | 0 | 0 | For |
| Capital Group | 748,230 | 0 | 0 | 0 | For |
| Capitol Series Trust | 725,855 | 0 | 0 | 0 | For |
| American Century | 724,702 | 0 | 0 | 0 | For |
| AllianceBernstein | 705,155 | 0 | 0 | 0 | For |
| Putnam | 653,905 | 0 | 0 | 0 | For |
| Equitable | 637,751 | 0 | 0 | 0 | For |
| Artisan | 468,338 | 0 | 0 | 0 | For |
| PROFESSIONALLY MANAGED PORTFOLIOS | 456,742 | 0 | 0 | 0 | For |
| Victory Capital | 422,252 | 0 | 0 | 0 | For |
| Jackson National | 403,486 | 0 | 0 | 0 | For |
| GLENMEDE FUND INC | 386,531 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 378,160 | 0 | 0 | 0 | For |
| BOSTON TRUST WALDEN FUNDS | 359,876 | 0 | 0 | 0 | For |
Showing the 25 largest of 136 asset managers. All 136 are in the interactive database (link above).
Combines 13 wordings of this item as funds reported it.
96% Approved · of votes cast
Prior year: 97.9% for (April 25, 2024 meeting) ▼ 1.8 pts
Description as filed by funds: To approve, by a non-binding advisory vote, the compensation of the Company's named executive officers.
HALOZYME THERAPEUTICS INC.’s own tally for this item (“2. The advisory vote on the compensation of the Company's named executive officers”): 98,252,464 for, 3,966,034 against — passed, per its Form 8-K filed May 2, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The foregoing proposal was approved.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,665,245 | 0 | 0 | 0 | For |
| BlackRock | 9,674,728 | 0 | 0 | 0 | For |
| Fidelity | 3,221,194 | 0 | 0 | 0 | For |
| State Street | 3,087,240 | 0 | 0 | 0 | For |
| Invesco | 0 | 2,072,322 | 0 | 0 | Against |
| Delaware/Macquarie | 1,970,939 | 0 | 0 | 0 | For |
| Charles Schwab | 1,756,673 | 0 | 0 | 0 | For |
| Dimensional | 1,435,550 | 0 | 0 | 0 | For |
| TIAA | 1,297,097 | 0 | 0 | 0 | For |
| JPMorgan | 1,112,323 | 0 | 0 | 0 | For |
| T. Rowe Price | 894,936 | 0 | 0 | 0 | For |
| First Trust | 797,531 | 0 | 0 | 0 | For |
| Capital Group | 748,230 | 0 | 0 | 0 | For |
| Capitol Series Trust | 725,855 | 0 | 0 | 0 | For |
| American Century | 724,702 | 0 | 0 | 0 | For |
| AllianceBernstein | 705,155 | 0 | 0 | 0 | For |
| Putnam | 653,905 | 0 | 0 | 0 | For |
| Equitable | 637,751 | 0 | 0 | 0 | For |
| Artisan | 468,338 | 0 | 0 | 0 | For |
| PROFESSIONALLY MANAGED PORTFOLIOS | 456,742 | 0 | 0 | 0 | For |
| Victory Capital | 422,252 | 0 | 0 | 0 | For |
| Jackson National | 403,486 | 0 | 0 | 0 | For |
| GLENMEDE FUND INC | 386,531 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 378,160 | 0 | 0 | 0 | For |
| BOSTON TRUST WALDEN FUNDS | 359,876 | 0 | 0 | 0 | For |
Fund voting reports, all 133 managers: 54,459,586 for, 2,413,515 against, 46,609 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| State Street | 6,490,642 | 0 | 0 | 0 | For |
| BlackRock | 4,907,930 | 997 | 0 | 0 | For |
| SNYDER CAPITAL MANAGEMENT L P | 3,463,937 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 3,093,192 | 0 | 0 | 0 | For |
| AllianceBernstein | 3,061,846 | 0 | 0 | 0 | For |
| MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 2,576,568 | 0 | 0 | 0 | For |
| Invesco | 0 | 2,232,464 | 0 | 0 | Against |
| JPMorgan | 2,098,231 | 0 | 0 | 0 | For |
| Charles Schwab | 1,782,214 | 0 | 0 | 0 | For |
| GW&K Investment Management, LLC | 1,536,178 | 0 | 0 | 0 | For |
| CONGRESS ASSET MANAGEMENT CO | 1,527,346 | 0 | 0 | 0 | For |
| ArrowMark Colorado Holdings LLC | 1,466,043 | 0 | 0 | 0 | For |
| Nuveen | 1,459,569 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,234,643 | 0 | 0 | 0 | For |
| Stephens Investment Management Group LLC | 1,096,531 | 0 | 0 | 0 | For |
| FULLER & THALER ASSET MANAGEMENT, INC. | 1,061,599 | 0 | 0 | 0 | For |
| Northern Trust | 1,028,170 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 985,106 | 0 | 0 | 0 | For |
| Artisan | 851,660 | 0 | 0 | 0 | For |
| Epoch Investment Partners, Inc. | 839,390 | 0 | 0 | 0 | For |
| American Century | 753,323 | 0 | 0 | 0 | For |
| Capital Group | 748,666 | 0 | 0 | 0 | For |
| Putnam | 712,317 | 0 | 0 | 0 | For |
| Janus Henderson | 648,298 | 0 | 0 | 0 | For |
| CAISSE DE DEPOT ET PLACEMENT DU QUEBEC | 638,507 | 0 | 0 | 0 | For |
Institutional-manager reports, all 416 managers: 59,583,137 for, 3,192,883 against, 52,687 abstained, 5,072 not voted, 61 unknown. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.4% Approved · of votes cast
Prior year: 99.4% for (April 25, 2024 meeting) unchanged
Description as filed by funds: To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
HALOZYME THERAPEUTICS INC.’s own tally for this item (“3. A proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025”): 112,028,211 for, 659,976 against — passed, per its Form 8-K filed May 2, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The foregoing proposal was approved.”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 136 asset managers below reported 56,920,151 for, 724 against, 46,609 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,665,245 | 0 | 0 | 0 | For |
| BlackRock | 9,674,728 | 0 | 0 | 0 | For |
| Fidelity | 3,221,194 | 0 | 0 | 0 | For |
| State Street | 3,087,102 | 138 | 0 | 0 | For |
| Invesco | 2,072,322 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,970,939 | 0 | 0 | 0 | For |
| Charles Schwab | 1,756,673 | 0 | 0 | 0 | For |
| Dimensional | 1,435,550 | 0 | 0 | 0 | For |
| TIAA | 1,297,097 | 0 | 0 | 0 | For |
| JPMorgan | 1,112,323 | 0 | 0 | 0 | For |
| T. Rowe Price | 894,936 | 0 | 0 | 0 | For |
| First Trust | 797,531 | 0 | 0 | 0 | For |
| Capital Group | 748,230 | 0 | 0 | 0 | For |
| Capitol Series Trust | 725,855 | 0 | 0 | 0 | For |
| American Century | 724,702 | 0 | 0 | 0 | For |
| AllianceBernstein | 705,155 | 0 | 0 | 0 | For |
| Putnam | 653,905 | 0 | 0 | 0 | For |
| Equitable | 637,751 | 0 | 0 | 0 | For |
| Artisan | 468,338 | 0 | 0 | 0 | For |
| PROFESSIONALLY MANAGED PORTFOLIOS | 456,742 | 0 | 0 | 0 | For |
| Victory Capital | 422,252 | 0 | 0 | 0 | For |
| Jackson National | 403,486 | 0 | 0 | 0 | For |
| GLENMEDE FUND INC | 386,531 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 378,160 | 0 | 0 | 0 | For |
| BOSTON TRUST WALDEN FUNDS | 359,876 | 0 | 0 | 0 | For |
Showing the 25 largest of 136 asset managers. All 136 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 123,170,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 11.91% |
| 2 | BlackRock | 7.85% |
| 3 | Fidelity | 2.62% |
| 4 | State Street | 2.51% |
| 5 | Invesco | 1.68% |
| 6 | Delaware/Macquarie | 1.60% |
| 7 | Charles Schwab | 1.43% |
| 8 | Dimensional | 1.17% |
| 9 | TIAA | 1.05% |
| 10 | JPMorgan | 0.90% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | State Street | 5.27% |
| 2 | BlackRock | 3.99% |
| 3 | SNYDER CAPITAL MANAGEMENT L P | 2.81% |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 2.51% |
| 5 | AllianceBernstein | 2.49% |
| 6 | MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 2.09% |
| 7 | Invesco | 1.81% |
| 8 | JPMorgan | 1.70% |
| 9 | Charles Schwab | 1.45% |
| 10 | GW&K Investment Management, LLC | 1.25% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| BlackRock | 17,092,111 | 13.88% | Form 13F, quarter ended March 31, 2025 |
| Vanguard Group | 12,831,503 | 10.42% | Form 13F, quarter ended March 31, 2025 |
| STATE STREET CORPORATION | 6,053,007 | 4.91% | Schedule 13G, filed May 13, 2025 |
| Invesco | 3,894,297 | 3.16% | Form 13F, quarter ended March 31, 2025 |
| Helen I. Torley | 2,505,521 | 2.03% | Proxy statement (DEF 14A), table as of March 4, 2025 |
| JPMorgan Chase | 2,474,825 | 2.01% | Form 13F, quarter ended March 31, 2025 |
| Dimensional Fund Advisors | 2,029,160 | 1.65% | Form 13F, quarter ended March 31, 2025 |
| Morgan Stanley | 1,931,474 | 1.57% | Form 13F, quarter ended March 31, 2025 |
| Charles Schwab | 1,748,851 | 1.42% | Form 13F, quarter ended March 31, 2025 |
| Northern Trust | 1,740,281 | 1.41% | Form 13F, quarter ended March 31, 2025 |
Percentages above are of 123,170,000 shares outstanding, as reported by HALOZYME THERAPEUTICS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At HALOZYME THERAPEUTICS INC.'s shareholder meeting held May 1, 2025, in the 2024-2025 proxy season, 512 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 2,632 separate fund positions. On the most widely held item on that ballot — To approve, by a non-binding advisory vote, the compensation of the Company's named executive… — HALOZYME THERAPEUTICS INC.'s filing reports the proposal as approved, with 96% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: HALOZYME THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 2, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from HALOZYME THERAPEUTICS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
HALOZYME THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Proxy Votes Now, “HALOZYME THERAPEUTICS (HALO) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/halozyme-therapeutics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.